FTC files preliminary injunction against CSL/Talecris
This article was originally published in Scrip
Executive Summary
The US Federal Trade Commission (FTC) has filed a preliminary injunction to block the proposed $3.1 billion merger of CSL and Talecris Biotherapeutics.